EXTENDED REPORT

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial

Philip G Conaghan,1 Patrick Durez,2 Rieke E Alten,3 Gerd-Rüdiger Burmester,4 Paul P Tak,5,6 Lars Klareskog,7 Anca Irinel Catrina,7 Julie DiCarlo,8 Corine Gaillez,9 Manuela Le Bars,9 Xianhuang Zhou,10 Charles Peterfy8

ABSTRACT

Objectives This randomised, double-blind, placebo-controlled phase IIIb study evaluated the impact of abatacept on MRI pathology as a primary outcome in methotrexate (MTX)-refractory patients with rheumatoid arthritis.

Methods Patients received intravenous abatacept (~10 mg/kg) or placebo, on background MTX, for 4 months, followed by an 8-month open-label extension (OLE; all patients received abatacept plus MTX). Patients had 1.5T MRI with intravenous contrast at baseline, Months 4 and 12; wrist synovitis (three locations assessed), and wrist and hand (15 and eight locations assessed, respectively) osteitis and erosion were scored using OMERACT-RAMRIS.

Results 26/27 abatacept- and 23/23 placebo-randomised patients completed Month 4 and entered the OLE; 26 and 21 completed Month 12. The primary endpoint was not achieved; mean change (SD) from baseline in synovitis was −0.44 (1.47) for abatacept versus 0.52 (1.38) for placebo (p=0.103) at Month 4. For mean change in synovitis adjusted for baseline score (sensitivity analysis), the difference between groups was −0.69, p=0.078. Adjusted mean changes (SE) in osteitis and erosion were −1.94 (0.86) and 0.45 (0.43) for abatacept, and 1.54 (0.90) and 0.95 (0.45) for placebo. Further MRI improvements were observed up to Month 12 for abatacept and from Months 4 to 12 for placebo-treated patients switched to abatacept at Month 4. Clinical efficacy was shown with abatacept and sustained to Month 12.

Conclusions Despite small patient numbers, MRI detected structural and synovial benefit, sustained to Month 12 in abatacept + MTX-treated patients, and improvements in structural and inflammatory outcomes for placebo + MTX-treated patients following addition of abatacept.

Clinical trial registration Clinicaltrials.gov NCT00420199.

INTRODUCTION

Evidence of joint destruction and bone loss in rheumatoid arthritis (RA)1–3 has created the need for reliable tools to accurately control the inflammatory process. MRI visualises bone damage (erosions) with increased sensitivity over conventional radiography and enables detection of synovial inflammation (synovitis) and bone oedema (osteitis).1–3 While early MRI studies used longitudinal observational cohorts to assess disease progression and therapeutic response,3 relatively few randomised controlled trials (RCTs) have included this technique as a key outcome.3 4 6–11

In clinical trials with intravenous abatacept—a fully human, recombinant fusion protein selectively modulating the CD80/CD86:CD28 costimulatory signal for full T cell activation—inhibition of radiographic damage progression was sustained over 5 years in patients with established RA, with an increasing inhibitory effect seen over 2 years in patients with early disease.12–17 The present exploratory ASSET (Impact of Intravenous Abatacept on Synovitis, Osteitis and Structural Damage in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate (MTX): A Randomised Controlled Trial) study aimed to evaluate the effect of abatacept versus placebo on MRI pathology and clinical efficacy and safety.

METHODS

Study design

ASSET was a phase IIIb randomised, double-blind (DB), placebo-controlled study of 4 months duration with an 8-month open-label extension (OLE), conducted at 11 medical centres in Europe (May 2007–August 2009). Patients were randomised 1:1 to receive abatacept (~10 mg/kg according to weight range) or placebo, plus background MTX, for 4 months. Randomisation was by central allocation of a unique number in order of qualification for treatment. Clinicians and patients were blinded; drug preparation professionals were unblinded.

Abatacept or placebo was administered intravenously on Days 1, 15, 29 and every 28 days up to and including Month 4. During the OLE all patients received abatacept every 28 days from Month 5 up to Month 12, plus background MTX. Patients exited early if they missed >2 consecutive doses; received high dose oral corticosteroids for >2 weeks; or were insufficiently controlled (at investigator discretion).
The primary endpoint was the difference between groups in mean change from baseline to Month 4 in wrist synovitis score; changes in wrist and hand osteitis and erosion were secondary endpoints. The study (clinicaltrials.gov: NCT00420199) was conducted in accordance with Good Clinical Practice, as defined by the International Conference on Harmonisation, and the ethical principles of the Declaration of Helsinki. Institutional review boards or independent ethics committees approved the protocol, and signed, written informed consent was provided by patients.

During the study, the following amendments to study design occurred. Patients could have moderate or high, instead of high, baseline disease activity, in order to improve the feasibility of the study and reflect the improving standard of RA care, given that MTX failure patients may not reach high disease activity before receiving a biologic. The timeframe during which intra-articular steroid injections were prohibited was reduced from 12 to 3 months prior to screening (initial restriction deemed too conservative).

**Patient population**

Patients (aged ≥18 years) had active RA (according to American Rheumatism Association (1987) criteria) ≤5 years’ duration. Active RA was defined as either Disease Activity Score 28 (DAS28) based on C reactive protein (CRP) >3.2 or a tender joint count of ≥6, a swollen joint count of ≥6 and a CRP measurement greater than the upper limit of normal. Patients had clinically detectable synovitis of at least the target wrist at screening and Day 1 and, in addition, ≥1 erosion present in the hands/wrists and/or feet (on previous radiographs) or were anticyclic citrullinated peptide (CCP) or rheumatoid factor (RF) positive. Patients had received MTX ≥15 mg/week or a maximum tolerated dose (≥10 mg/week) for ≥3 months prior to Day 1 (stable dose ≥28 days prior to first study dose).

**Concomitant medications**

Permitted concomitant medications throughout the 12-month study included stable dose MTX (10–25 mg/week; decreases permitted for toxicity during DB) and a stable, low dose of oral corticosteroids (reduced to equivalent ≤10 mg/day prednisolone for 28 days). Intra-articular or intramuscular corticosteroid injections were not permitted from 3 months prior to Day 1. In the OLE, one intramuscular, intra-articular or high dose oral corticosteroid course (defined as >10 mg/day equivalent of prednisolone for ≥3 consecutive days) was allowed at the discretion of the investigator until the clinical situation had resolved; no intra-articular injections were permitted for the last month of the OLE.

**MRI assessments**

Patients had 1.5 Tesla MRI, T1W–coronal short-τ inversion recovery (469×625×3000 μm voxels) and fat-suppressed 3D gradient-echo plus intravenous gadolinium contrast of the same wrist (based on clinical involvement) and fat-suppressed 3D gradient-echo plus intravenous gadolinium contrast of one hand and wrist (based on clinical involvement) and fat-suppressed 3D gradient-echo plus intravenous gadolinium contrast of the same wrist—at baseline (Day 1), Month 4 (Day 113) and Month 12 (Day 337). A single expert radiologist, blinded to both treatment assignment and time order, scored all images for synovitis, osteitis and bone erosion according to the OMERACT rheumatoid arthritis MRI score (RAMRIS) method. Images were checked for technical quality and read by a central facility. Two MRI readings were independently made: (1) baseline and Month 4 timepoints (prespecified analysis of the DB period) and (2) baseline, Month 4 and Month 12 timepoints (OLE analysis). The baseline and Month 4 MRIs were reread at the second reading to maintain reader blinding to timepoint order. Intraclass correlation coefficients for the two readings were: 0.87 (synovitis), 0.98 (osteitis) and 0.94 (erosion) for baseline MRI scores; 0.89 (synovitis), 0.96 (osteitis) and 0.94 (erosion) for Month 4 MRI scores; and 0.70 (synovitis), 0.86 (osteitis) and 0.55 (erosion) for change from baseline to Month 4 MRI scores.

The proportions of MRI non-progressors for synovitis, osteitis and erosion were evaluated, defined as patients with MRI score change <1 unit from baseline. For further details on the joints that were assessed by MRI and how scoring was performed, please see the online supplementary appendix.

**Clinical efficacy**

Disease activity was assessed at each study visit until Month 6, and then at Months 9 and 12 using DAS28 (composite of four variables: 28 tender joint count, 28 swollen joint count, CRP and patient assessment of disease activity (visual analogue scale)) and Simplified Disease Activity Index (SDAI; CRP). DAS28-defined low disease activity state (LDAS: DAS28≤3.2) and remission (DAS28<2.6), and SDAI-defined LDAS (SDAI≤11) and remission (SDAI≤3.3) were determined.

**Safety**

Adverse events (AEs), serious AEs and AEs of interest, including infections, malignancies and prespecified acute infusional reactions, were assessed in patients who received at least one dose of abatacept. See online supplementary appendix for further details.

**Statistics**

A total of 50 randomised patients yielded ≥87% power to detect an improvement of 1.44 units in the primary endpoint between the treatment arms using a non-parametric two-sided Wilcoxon test at the 5% significance level. Sample size calculation was based on three previous studies.

For the primary endpoint, comparisons between groups in mean change in wrist synovitis from baseline to Month 4 (based on first reading of baseline and Month 4 MRIs) were based on non-parametric analysis of covariance (ANCOVA), with the rank score for change from baseline in total wrist synovitis score as dependent variable, treatment group as main effect and rank score for total wrist synovitis score at baseline as additional covariate. The p value for the comparison, with significance level 0.05, was calculated. As probability plots did not reveal deviations from normality in changes from baseline in wrist synovitis score to Month 4, a post hoc sensitivity analysis of the primary endpoint was performed using a parametric ANCOVA, allowing for estimation of the adjusted mean difference between treatment groups. In this sensitivity analysis, change from baseline was the dependent variable, treatment group was the main effect and baseline value an additional covariate.

Adjusted mean changes in synovitis, osteitis and erosion scores from baseline to Month 4, from baseline to Month 12, and from Month 4 to Month 12 were calculated. Adjustment was based on an ANCOVA model with treatment as factor and baseline value as covariate, no between-group comparisons were made. No formal statistical testing was applied to any of the clinical efficacy outcome analyses.

MRI scores and clinical efficacy up to Month 4 are presented for the modified intent-to-treat population, which included all patients randomised and treated with data available at baseline.
and visit of interest (as-observed). Results up to Month 12 (OLE) are presented for patients treated in the OLE with data available at baseline and visit of interest (as-observed).

RESULTS

Patient disposition and baseline demographics

Of 50 randomised and treated patients (abatacept (n=27) and placebo (n=23)), one (abatacept group) discontinued the DB period due to no longer meeting study criteria (hyperparathyroidism). Of the 49 patients who entered the OLE, 47 (95.9%) completed the study. Two patients, both originally randomised to placebo, discontinued the OLE (see online supplementary figure S1).

Baseline disease characteristics for patients randomised and treated in the DB period were generally similar between groups, although more patients in the placebo versus abatacept group were RF or anti-CCP positive (table 1) and baseline synovitis and erosion scores were higher in the abatacept group (figure 1A).

Concomitant medications and drug exposure

At randomisation, concomitant medications were comparable between groups (table 1), and use remained relatively stable throughout DB treatment. During the OLE, all patients continued to receive MTX; 18 (69.2%) and 15 (65.2%) patients in the original abatacept group and the original placebo group, respectively, received low dose corticosteroids (≤10 mg prednisolone equivalent; mean dose: 3.7 and 3.1 mg/day, respectively).

One patient received more than one course of high dose corticosteroids and one patient received more than two intra-articular steroid injections (both original placebo group). The mean (SD) total duration of abatacept exposure across the DB and OLE was 15.2 (0.20) months in the original abatacept group and 8.3 (0.84) months in the original placebo group switched to abatacept at Month 4.

MRI assessments

Primary endpoint: Month 4 (first reading)

Mean MRI scores at baseline and Month 4, according to the first MRI reading, are shown in figure 1A. From baseline to Month 4, reduction in wrist synovitis score (primary endpoint) was seen for the abatacept group (mean change (SD): −0.44 (1.47), n=25) compared with worsening of wrist synovitis for the placebo group (mean change (SD): 0.52 (1.38), n=25), but the difference between treatment groups was not significant (p=0.103).

Sensitivity analysis of primary endpoint: Month 4 (first reading)

The sensitivity analysis adjusted for baseline synovitis score using a parametric ANCOVA. In this analysis, mean change (SE) in synovitis was −0.51 (0.26) for abatacept versus 0.38 (0.27) for placebo (figure 1A). Difference between treatment groups in adjusted mean synovitis score change approached significance (−0.69 (95% CI −1.45 to 0.08); p=0.078).

Adjusted mean change in osteitis and erosion: Month 4 (first reading)

A greater reduction in adjusted mean (SE) osteitis score from baseline to Month 4 was observed in the abatacept (n=25) versus placebo (n=23) group: −1.94 (0.86) versus 1.54 (0.90), respectively (figure 1A). Erosion progression was also reduced in the abatacept versus placebo group at Month 4 with adjusted mean change (SE) from baseline in erosion scores of 0.45 (0.43) versus 0.95 (0.45), respectively (figure 1A).

Month 4 (second reading) MRI outcomes

Data from the second MRI reading (baseline and Month 4 were reread at Month 12; figure 1B–D, left-hand panels) were generally consistent with the MRI data from the first reading.

MRI analysis: Month 12

In the original abatacept group, further improvements in wrist synovitis and wrist and hand osteitis were seen from Months 4 to 12 (figure 1B,C; middle and right-hand panels). In the original placebo group, reductions in synovitis and osteitis were seen after addition of abatacept at Month 4, and by Month 12 the changes from baseline in synovitis and osteitis were similar to those seen in the original abatacept group. Reduced progression of erosion was seen in the original abatacept group from Month 4 to Month 12 with continued treatment (figure 1D; middle and right-hand panels). Erosion score was also reduced in the original placebo group following addition of abatacept at Month 4, although the extent of this reduction was not as great as that seen in the original abatacept group by Month 12.

MRI non-progressors: Months 4 and 12

A higher proportion of patients in the abatacept group demonstrated non-progression of synovitis and osteitis at Month 4 compared with the placebo group (figure 2; left-hand panels). At Month 12, the proportions of MRI non-progressors for each outcome in the original placebo group switched to abatacept were generally similar to those in the original abatacept group (figure 2; right-hand panels).

Table 1 Baseline demographic and clinical characteristics for randomised and treated patients

<table>
<thead>
<tr>
<th></th>
<th>Abatacept + MTX (n=27)</th>
<th>Placebo + MTX (n=23)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>51.7±11.2</td>
<td>52.5±11.5</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>16 (59.3)</td>
<td>16 (69.6)</td>
</tr>
<tr>
<td>Caucasian, n (%)</td>
<td>26 (96.3)</td>
<td>19 (82.6)</td>
</tr>
<tr>
<td>Duration of RA (months)</td>
<td>25.7±18.0</td>
<td>28.2±17.0</td>
</tr>
<tr>
<td>Tender joints, n</td>
<td>12.9±7.1</td>
<td>13.3±7.2</td>
</tr>
<tr>
<td>Swollen joints, n</td>
<td>11.3±6.6</td>
<td>8.5±4.1</td>
</tr>
<tr>
<td>Patient global assessment, VAS 100 mm</td>
<td>50.9±24.7</td>
<td>56.6±24.4</td>
</tr>
<tr>
<td>Physician global assessment, VAS 100 mm</td>
<td>51.5±18.7</td>
<td>57.4±15.1</td>
</tr>
<tr>
<td>Positive RF status, n (%)*</td>
<td>15 (55.6)</td>
<td>19 (82.6)</td>
</tr>
<tr>
<td>Positive anti-CCP2 status, n (%)*</td>
<td>13 (48.1)</td>
<td>17 (73.9)</td>
</tr>
<tr>
<td>DAS28 (CRP)</td>
<td>5.3±1.1</td>
<td>5.3±0.9</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>13.6±17.4</td>
<td>16.6±16.8</td>
</tr>
<tr>
<td>CDAI</td>
<td>34.4±15.3</td>
<td>32.2±10.3</td>
</tr>
<tr>
<td>SDAI (CRP)</td>
<td>35.8±16.1</td>
<td>34.9±10.8</td>
</tr>
<tr>
<td>Concomitant medications at baseline, n (%)</td>
<td>100 mm</td>
<td>100 mm</td>
</tr>
<tr>
<td>MTX</td>
<td>23 (100)</td>
<td>27 (100)</td>
</tr>
<tr>
<td>MTX dose, mean±SD mg/week</td>
<td>16.9±4.6</td>
<td>17.3±4.2</td>
</tr>
<tr>
<td>Oral and/or injectable corticosteroids</td>
<td>19 (70.4)</td>
<td>14 (60.9)</td>
</tr>
<tr>
<td>Low dose oral corticosteroids</td>
<td>16 (59.3)</td>
<td>12 (52.2)</td>
</tr>
<tr>
<td>Oral dose of corticosteroids, mean±SD</td>
<td>3.9±3.51</td>
<td>3.0±3.72</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>22 (81.5)</td>
<td>20 (87.0)</td>
</tr>
</tbody>
</table>

Values are means±SD unless stated otherwise.

*Per the inclusion criteria, if patients were not RF or anti-CCP2 positive, they had to have radiographic evidence of erosion.

Cyclical citrullinated protein; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; DAS28, Disease Activity Score 28; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index; VAS, visual analogue scale.
Disease activity assessments
Mean reductions (95% CI) from baseline to Month 4 and Month 12 in DAS28 (CRP) and SDAI are shown in online supplementary figure S2. A higher proportion of patients from the original abatacept group reached remission and LDAS (DAS28- and SDAI-defined) at Month 12 than at Month 4 (figure 3A). At Month 12, the proportion of patients reaching remission and LDAS according to both DAS28 and SDAI criteria remained greater in the original abatacept group than in the original placebo group (figure 3).

A post hoc analysis examined the relationship between disease activity at Month 4 and MRI scores at Month 12 in patients treated in the OLE who were originally randomised to abatacept (table 2). Greater reductions in erosion progression and synovitis score at Month 12 were seen for patients with lower versus higher disease activity at Month 4. Osteitis score at Month 12 was reduced regardless of Month 4 disease activity.

Safety
A summary of AEs is reported in table 3 and in online supplementary appendix. Most AEs were considered mild or moderate in intensity, and none resulted in withdrawal.

**DISCUSSION**
In the phase IIIb, exploratory, ASSET study, intravenous abatacept plus MTX was associated with reductions in synovitis and osteitis and less progression of erosion, compared with placebo plus MTX; increased proportions of abatacept-treated patients experienced non-progression of synovitis and osteitis after 4 months compared with patients receiving placebo plus MTX. A persistent beneficial effect on osteitis and synovitis was observed in patients who remained on abatacept over 12 months, with inhibition of erosion progression also seen. Following addition of abatacept, patients initially randomised to placebo achieved incremental reductions in synovitis and osteitis after 4 months compared with patients receiving placebo plus MTX. These patients also showed reduced progression in erosion score after initiating abatacept. MRI assessment of abatacept-treated patients has previously been reported in the ADJUST trial in MTX-naive patients with very early or undifferentiated inflammatory arthritis, and in patients with psoriatic arthritis.23 24 The improvements in MRI synovitis, osteitis and erosion progression seen here with abatacept plus MTX over 12 months are consistent with...
findings from those trials, and with pharmacodynamic data that suggest abatacept may have a positive effect on bone metabolism through its regulatory effect on osteoclast differentiation and bone resorption. The degree of local baseline inflammation, both synovitis and osteitis, predicts erosion progression during early disease. Consequently, improving osteitis scores may favourably impact the long-term prognosis of erosion progression. Indeed, inhibition of erosion progression was seen over 12 months of abatacept plus MTX treatment for patients in this study, but was not observed by Month 4.

The beneficial MRI outcomes seen with abatacept are also consistent with those reported for conventional disease-
modifying antirheumatic drugs and other biologics, with recent RCTs documenting the beneficial effects on MRI assessments of infliximab, adalimumab and golimumab in patients with early RA, and of denosumab, fostamatinib, tocilizumab, rituximab and golimumab in patients with established disease. However, caution must be used when making comparisons across these trials owing to general differences, such as differing magnet field strengths, pulse sequence parameters, the use of contrast agents and the anatomical locations assessed (eg, metacarpophalangeal joints and wrists vs wrists alone, as in the current study).

Abatacept treatment improved disease activity over time in this study, consistent with previous abatacept trials, although the proportion of patients achieving treatment targets (based on DAS28 and SDAI) was higher in the current study, probably because these patients had less severe disease at baseline. Patients originally randomised to placebo who switched to abatacept at Month 4 experienced improvements in disease activity by Month 12 that approached those observed in patients continuously treated with abatacept. However, the proportions of patients achieving DAS28 LDAS and DAS28 and SDAI remission at Month 12 suggest that although disease activity improves when patients switch to abatacept, many of them do not reach the low states of disease activity seen in patients who are continuously treated with abatacept.

Control of disease status at Month 4 in the original abatacept group was associated with greater numerical improvements in synovitis and erosion at Month 12. Reductions in osteitis were seen regardless of the level of disease activity at Month 4. The disconnect between osteitis and clinical efficacy, where osteitis improved in the context of persistent clinical disease, may be due to the regulatory effect of abatacept on bone, discussed above, or the presence of subclinical disease. Consequently, the reported positive effect on osteitis may result in better long-term structural prognostic regardless of initial clinical efficacy outcomes.

Abatacept was well tolerated by patients, with a high retention rate in both the DB period and OLE. No new safety signals were identified in the OLE relative to the DB period, and overall safety was consistent with previous reports of abatacept.

Certain limitations of this study need to be taken into account. Guidance for powering MRI studies remains uncertain, including the number of anatomical sites to be evaluated and the responsiveness of the scoring system for each pathological feature. This is a direct result of the paucity of published MRI RCTs at the time the study was designed. Therefore, extrapolation of data from previous MRI RCTs to determine the sample size and anatomical sites may have been imprecise and, as such, this study should be considered exploratory. Assessment of synovitis in this study was restricted to the wrist; contrast-enhanced images of the MCP joints were not acquired owing to limitations in MRI examination time. Additionally, osteitis and erosion were not assessed at MCP 1, as per recent modification of RAMRIS.15 Another limitation is that the MRI images were read and scored by only one reader; it has been demonstrated that averaging scores from additional readers can reduce error.11 Had two MRI readers been used, and a greater number of patients included in the study, the findings for the primary and secondary outcomes may have been different. Finally, the limited number of patients included in this study, and the difference in proportions of RF and anti-CCP positive patients between groups, should also be taken into account when interpreting the analyses. While small MRI studies are suitable for exploring mechanisms of action, the limited number of patients leads to difficulties in interpreting the relationship between a small number of MRI assessed sites and systemic assessment of disease activity.

Even with the wrist-only assessments of synovitis, abatacept plus MTX was associated with reductions in osteitis, minimal deterioration in erosion and a trend toward reduced MRI synovitis versus placebo plus MTX over 4 months, demonstrating an early effect of abatacept on inflammation and structural damage. With continued treatment, patients initially randomised to abatacept experienced persistent benefit in synovitis and osteitis, with inhibition of erosion progression; patients initially randomised to placebo achieved incremental reductions in MRI assessed inflammation and slowing of erosion progression after switching to abatacept. In conclusion, data from the ASSET study extend current knowledge on the early effect of intravenous abatacept on synovium and bone and confirm its use as an effective and well-tolerated therapeutic option in patients with RA who have previously failed MTX therapy.

Acknowledgements The authors would like to thank Eve Guichard (Medicus International) for her editorial assistance and Conal Percot, Keqin Qi (both Bristol-Myers Squibb) and Harry Genant, (UCSF/Synarc) for their expertise and assistance in data analysis and interpretation. The authors and study sponsors would also like to thank the patients and coworkers at the study sites, and the following primary investigators: from Belgium: Yves Boutsen, Catherine Leens, Marie Avaux, Isabelle Focant, Frederic Houssiau, Bernard Lauweryns, Laurent Mercier De Belfllof, Adrien Nezussu, Maria Stenou and Marie Vanthuyne; from Germany: Karlrid Reindolf Aupperle, Hans Bastian, Robert Biesen, René Dzurlina, Eugen Feist, Thomas Haepel, Arndt Jacobs, Bettina Marsmann, Jan Zarnicke, Svetlana Djacenko and Christof Pohl; from Spain: Jesus Rodriguez Moreno, Juan De Dios Carrete, Victoria Hernandez, Concepcion Moll Tuduri, Africa Musi and Raimond Sammartini; from Sweden: Alkertier Chatziotyios, Louise Eklom, Anders Harju, Aase Hensvold, Peter Matt, Petra Neregard, Harald Rezaei, Christina Stranger and Anna Vikerfors; from The Netherlands: Mariann Anson, Maarit J.H. Boumans, Marjolein Johanna Helena De Haer, DM Gerlag, Krista Klara Maria Glas, Marieke Margriet Jeanne Heneus, Ducu Pocorni and Angelina J.K. Roelse; and from the UK: Paul Emery, Shovik Dass, Helen Haeupl, Annett Jacobi, Bettina Marsmann, Jan Zernicke, Svetlana Djacenko and Christof Pohl; from France: Josefa Rodriguez Moreno, Juan De Dios Carrete, Victoria Hernandez, Concepcion Moll Tuduri, Africa Musi and Raimond Sammartini; from Sweden: Alkertier Chatziotyios, Louise Eklom, Anders Harju, Aase Hensvold, Peter Matt, Petra Neregard, Harald Rezaei, Christina Stranger and Anna Vikerfors; from The Netherlands: Mariann Anson, Maarit J.H. Boumans, Marjolein Johanna Helena De Haer, DM Gerlag, Krista Klara Maria Glas, Marieke Margriet Jeanne Heneus, Ducu Pocorni and Angelina J.K. Roelse; and from the UK: Paul Emery, Shovik Dass, Helen Haeupl, Alkon Mcruman, Sharmin Nizam, Richard Reece, Laura Rhodes, Benazir Saleem, Nita Sternet, Laszlo Szabo and Edward Vital.

Contributors PCG, PG, RA, GRB, PPT, LK, AIC and CP contributed to the acquisition of the data. All authors contributed to the analysis and interpretation of the data and were involved in drafting the article and revising it critically for important intellectual content. This version was approved by all authors for submission/publication.

Funding This study and the editorial support received were funded by Bristol-Myers Squibb.
Competing interests P Conaghan has received speaker honoraria, research grants or attended advisory boards for AstraZeneca, Bristol-Myers Squibb, Centocor, Merck, Novartis, Pfizer and Roche. P Durez has received speaker honoraria from Bristol-Myers Squibb, Pfizer, Abbott and Merck. R Aten has received research grants from Bristol-Myers Squibb, Merck, Pharma GmbH, Novartis, UCB, Roche, Wyeth Pharmaceuticals and Pfizer, speaker honoraria from Abbott Laboratories, Bristol-Myers Squibb, Horizon Pharma, Novartis and Roche, and consulting fees from Abbott Laboratories, Horizon Pharma, Novartis and Roche. G Burmester has received consulting fees from Abbott Immunopharmacology Pharmaceuticals, BMS, Roche, Merck and Pfizer, research grants from Abbott Laboratories, Abbott Immunopharmacology Pharmaceuticals, Bristol-Myers Squibb and Roche, and speaker honoraria from Abbott Immunopharmacology Pharmaceuticals, Bristol-Myers Squibb and Roche. PP Tak has received consulting fees from Abbott Laboratories, Bristol-Myers Squibb, Genentech, Inc. and Roche, is founder of Arthrogen B.V. Amsterdam, and has received research grants from Bristol-Myers Squibb, Genentech, Inc. and Roche. L Kläreskö has received research grants from Centocor Research and Development Inc., Roche, Pfizer, Bristol-Myers Squibb and Abbott. Al Catrina has received grants/research support from: Abbott, Roche and Centocor and speaker honoraria/consultant fees from: Bristol-Myers Squibb, Abbott, Roche and MSD; J DiCarlo is an employee of Spire Sciences and has received consulting fees from AstraZeneica, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, Hoffmann-La Roche, Merck, Novartis, Rigel, Roche, Sandi-Aventis and UCB. C Gallez, M Le Bars and X Zhou are employees of Bristol-Myers Squibb. C Peterfy has received consulting fees from Abbott Laboratories, Amgen Inc., Astellas Pharma, AstraZeneca, Genentech, Inc, Bristol-Myers Squibb, Genentech, Inc., Crescendo, Genentech, Hoffmann-La Roche, Inc., Lilly USA, LLC, Merck Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pfizer Inc, Regeneron Pharmaceuticals, Inc., Rigel Pharma, Roche, Samsung Pharmaceutical, UCB, Inc. and Wyeth Pharmaceuticals, and is the founder and CEO of Spire Sciences, LLC.

Ethics approval The laws and regulatory requirements of all countries participating in this study were adhered to. This study was conducted in accordance with Good Clinical Practice, as defined by the International Conference on Harmonisation and in accordance with the ethical principles underlying European Union Directive 2001/20/EC and the USA Code of Federal Regulations, Title 21, Part 50 (21 CFR50). The protocol, amendments and subject-informed consent received appropriate approval by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) prior to initiation of study at the site. Each IRB/IEC was composed of a review panel that was responsible for ensuring the protection of the rights, safety and well-being of human subjects involved in the clinical investigation and was adequately constituted to provide assurance of that protection. The IRB/IECs consulted during this study can be provided as a separate document.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The IRB/IECs consulted during this study can be provided as a separate document. No additional unpublished data from this study are available as a separate document. No additional unpublished data from this study are available as a separate document.


